AOD-9604 and Rosuvastatin Interaction: What the Evidence Actually Says

What Is AOD-9604 and How Is It Used?

AOD-9604 is a synthetic peptide consisting of amino acids 176 to 191 of human growth hormone, with a tyrosine residue added at the N-terminus. It was originally developed by Monash University researchers as a lipolytic agent that retains the fat-mobilizing activity of GH without the insulin-desensitizing effects seen with full-length GH administration. The peptide does not bind the GH receptor and does not raise IGF-1 levels at studied doses, which separates its metabolic profile sharply from exogenous GH therapy.

Regulatory and Prescribing Context

AOD-9604 carries no FDA-approved New Drug Application. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act may prepare it for individual patients when a licensed prescriber issues a valid prescription. The FDA has not evaluated AOD-9604 for safety or efficacy in any approved indication. That regulatory gap means there is no FDA-mandated drug interaction section, no package insert, and no sponsor-submitted pharmacokinetic dataset available to clinicians.

Mechanism of Fat Metabolism Effects

In preclinical work, AOD-9604 stimulated lipolysis in adipocytes through a beta-3 adrenergic receptor-dependent pathway and inhibited lipogenesis. A 12-week randomized placebo-controlled trial (N=300) sponsored by Metabolic Pharmaceuticals tested oral AOD-9604 at doses ranging from 1 mg to 30 mg daily in adults with obesity and found no significant weight loss compared to placebo at any dose tested, with a safety profile comparable to placebo 1. The injectable subcutaneous form used in compounding practice differs from that oral formulation, and no published RCT has examined the injectable route in humans.

How Rosuvastatin Is Absorbed, Transported, and Eliminated

Rosuvastatin's pharmacokinetic behavior is unusually well-characterized because it has been the subject of multiple transporter-specific interaction studies cited in regulatory submissions. Understanding those pathways is the starting point for any interaction analysis.

Hepatic Uptake Transporters: OATP1B1 and OATP1B3

After oral dosing, rosuvastatin reaches peak plasma concentration in approximately 3 to 5 hours. Hepatic uptake depends heavily on OATP1B1 (encoded by SLCO1B1) and OATP1B3. The FDA's rosuvastatin label (Crestor, AstraZeneca) states that co-administration with cyclosporine, a potent OATP inhibitor, increases rosuvastatin AUC by approximately 7-fold, which is the basis for the absolute contraindication with cyclosporine 2. Even moderate OATP1B1 inhibitors such as gemfibrozil increase rosuvastatin AUC by roughly 1.9-fold in clinical studies 2. Those numbers matter because myopathy risk scales with plasma exposure.

BCRP and Intestinal Efflux

The breast cancer resistance protein (BCRP, gene ABCG2) limits intestinal absorption of rosuvastatin. Subjects carrying the ABCG2 c.421C>A variant (minor allele frequency roughly 30% in East Asian populations, approximately 10% in European populations) show rosuvastatin AUC values 1.7- to 2.4-fold higher than wild-type carriers 3. The FDA label recommends a maximum dose of 20 mg rosuvastatin in patients known to carry this variant 2.

CYP Metabolism: Minimal but Present

Rosuvastatin undergoes limited hepatic metabolism via CYP2C9, accounting for roughly 10% of its clearance. That minor contribution means CYP2C9 inhibitors rarely produce clinically significant rosuvastatin interactions on their own, though they can compound transporter-mediated exposure increases when both mechanisms are affected simultaneously 4.

Does AOD-9604 Interact with Rosuvastatin's Transport Pathways?

No published human study has tested AOD-9604 as an OATP1B1, OATP1B3, or BCRP inhibitor. Short peptides are not typical substrates or inhibitors of these transporters. Most drug transporter inhibition involves lipophilic small molecules with molecular weights below 600 Da that bind the transporter's substrate-binding domain. AOD-9604 is a 15-amino-acid peptide with a molecular weight of approximately 1815 Da and a predominantly hydrophilic character, making transporter inhibition pharmacologically unlikely based on structural grounds alone.

What "Pharmacologically Unlikely" Does Not Mean

Unlikely is not impossible. The FDA's 2020 guidance on drug interaction studies recommends in vitro transporter assays for any new molecular entity before human trials, and that work has simply never been done for AOD-9604 in a regulatory context 5. Without those assays, a definitive statement that AOD-9604 is OATP-neutral cannot be made. Clinicians are left reasoning from structural analogy, which is a weaker form of evidence than a direct assay.

CYP2C9 Interaction Likelihood

AOD-9604 has no published human CYP inhibition profile. Peptide drugs generally do not inhibit CYP enzymes because they lack the planar aromatic or nitrogen-containing structures that coordinate with the CYP heme iron. Semaglutide, another GLP-1-related peptide, showed no clinically meaningful CYP interactions in its pharmacokinetic studies, though semaglutide and AOD-9604 are structurally distinct 6. That analogy is suggestive, not confirmatory.

Pharmacodynamic Interaction: Lipid and Muscle

A pharmacodynamic interaction occurs when two agents affect the same biological endpoint rather than each other's blood levels. AOD-9604 has been proposed to alter lipid metabolism through lipolytic activity. If that activity were meaningful in humans, it could theoretically change the lipid milieu in which rosuvastatin acts, though no data support a clinically significant PD interaction at this time. The myopathy pathway is more relevant: rosuvastatin-associated myopathy risk at 20 mg is approximately 0.1% annually in clinical trial populations 7. Factors that increase muscular metabolic demand or reduce mitochondrial function could theoretically amplify that risk, but AOD-9604 has no published evidence of either effect.

Severity Classification and Clinical Risk Rating

Because no direct interaction study exists, a formal DDI severity classification requires inferential reasoning from what is known. The table below applies the standard DDI severity framework used by Lexicomp and Micromedex to this pair, with the evidence basis for each domain made explicit.

| Domain | Evidence Available | Inferred Risk | |---|---|---| | PK: OATP1B1/1B3 inhibition by AOD-9604 | None (no in vitro or human data) | Low; structural grounds argue against | | PK: BCRP inhibition by AOD-9604 | None | Low | | PK: CYP2C9 inhibition by AOD-9604 | None | Low | | PD: Myopathy pathway | No shared pathway identified | Low; baseline monitoring still warranted | | PD: Lipid endpoint overlap | Theoretical only | Not clinically established | | Overall inferred severity |, | Low to moderate (data-limited) |

A "data-limited" classification is not a clean bill of health. It reflects absence of evidence rather than evidence of absence. The 2023 American College of Cardiology/American Heart Association cholesterol guideline emphasizes that statin safety decisions should account for individual patient factors including genetic SLCO1B1 variants, concurrent medications, and baseline CK levels before any regimen change 8.

What Happens to Rosuvastatin Exposure If Transporter Function Is Altered?

It is worth understanding the exposure-response relationship for rosuvastatin myopathy, even if AOD-9604 is unlikely to shift that exposure. A 2021 analysis of the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) cohort identified SLCO1B1 rs4149056 as significantly associated with simvastatin myopathy risk (odds ratio 4.5 per allele copy, P<0.001), establishing the principle that hepatic uptake transporter genotype is a dominant determinant of muscle toxicity risk across the statin class 9. Similar but less pronounced associations exist for rosuvastatin and SLCO1B1 variants 10.

The practical implication: patients on rosuvastatin who carry high-risk SLCO1B1 or ABCG2 variants already have elevated baseline plasma exposure. Any additional factor that further increases exposure, even modestly, moves them closer to the myopathy threshold. Those patients warrant particular attention when any new agent is added, including compounded peptides without established transporter profiles.

Dose-Dependent Exposure Data for Rosuvastatin

At 10 mg, mean rosuvastatin Cmax is approximately 37 ng/mL. At 40 mg, it rises to approximately 121 ng/mL, with AUC scaling roughly linearly 2. The 7-fold AUC increase seen with cyclosporine co-administration would theoretically push a 10 mg dose into the pharmacokinetic equivalent of 70 mg, a dose that does not exist commercially because it exceeds the approved maximum of 40 mg. That magnitude illustrates why transporter inhibition matters even at baseline-approved statin doses.

Monitoring Protocol for Patients Taking Both Agents

Given the data gap, the appropriate clinical response is structured monitoring rather than reflexive contraindication or uncritical permissiveness. The following protocol is consistent with the ACC/AHA 2023 cholesterol guideline's monitoring recommendations for patients on statin therapy 8.

Before Starting AOD-9604

• Obtain baseline creatine kinase (CK). A CK more than 4 times the upper limit of normal is a reason to pause and investigate before adding any new agent.
• Review the patient's rosuvastatin dose and duration. Patients on 40 mg for more than 12 months without myalgia are at lower near-term risk than those recently uptitrated.
• Ask about SLCO1B1 or ABCG2 genetic testing results if available. Pharmacogenomic results from prior panels may be in the chart.
• Document the current lipid panel. AOD-9604 proponents sometimes claim lipid effects; baseline data allows objective reassessment.

During Co-Administration

Repeat CK at 6 to 8 weeks after starting AOD-9604. Any new myalgia, unexplained fatigue, or dark urine warrants same-week CK measurement and temporary rosuvastatin hold pending results. The FDA label defines myositis as CK more than 10 times the upper limit of normal with symptoms, and rhabdomyolysis as CK more than 40 times the upper limit of normal with renal involvement 2.

Stopping Rules

Hold rosuvastatin immediately and contact the prescribing physician if CK exceeds 10 times the upper limit of normal on any measurement, symptoms of rhabdomyolysis appear (muscle pain with cola-colored urine, oliguria, or acute kidney injury), or hepatic transaminases rise above 3 times the upper limit of normal on two consecutive measurements 2.

Patient Counseling Points

Patients asking about this combination deserve honest, jargon-free information. The following points reflect the evidence base accurately.

On safety: The combination has not been studied. That is not a reassurance of safety; it is a statement of what is unknown. Rosuvastatin is an approved medication with a well-characterized safety profile. AOD-9604 is a compounded peptide with no FDA-approved indication and limited human clinical data.

On muscle symptoms: Any new muscle pain, weakness, or cramping after starting AOD-9604 while on rosuvastatin should be reported the same day rather than waited out. Statin myopathy is reversible when caught early and becomes dangerous when ignored 7.

On not self-adjusting doses: Some patients assume that taking less rosuvastatin while adding AOD-9604 is a safety hedge. Reducing a statin dose without medical direction removes documented cardiovascular protection. The JUPITER trial (N=17,802) showed rosuvastatin 20 mg reduced first major cardiovascular events by 44% versus placebo (hazard ratio 0.56, 95% CI 0.46 to 0.69, P<0.001) 11. That benefit is not worth trading away on the basis of a theoretical interaction risk.

On disclosure: Patients should tell every prescriber and pharmacist they are using AOD-9604. Compounded peptides are often perceived as supplements and omitted from medication lists, which creates blind spots in interaction screening.

What Prescribers Should Document

A prescriber considering this combination should record in the chart: the rationale for AOD-9604 use, the patient's current rosuvastatin dose and indication, baseline CK and lipid values, any known pharmacogenomic results relevant to statin metabolism, a discussion of the data limitations with the patient, and a monitoring schedule. That documentation satisfies the standard of care for off-label compounded agent co-prescribing and creates a clear record if an adverse event occurs.

The ACC/AHA 2023 guideline states: "Clinicians should assess and discuss statin-associated side effect risk with patients before initiation and at follow-up visits, using shared decision-making that incorporates patient preferences and values" 8. A compounded peptide added to an existing statin regimen falls squarely within that framework.

The Broader AOD-9604 Drug Interaction Field

Rosuvastatin is not the only medication worth considering in patients using AOD-9604. Because AOD-9604's full pharmacokinetic profile in humans is unpublished, any co-administered drug that relies on OATP, BCRP, or renal transporter function deserves a similar level of scrutiny. Agents in this category include methotrexate, repaglinide, and sulfasalva-class compounds. Insulin and GLP-1 receptor agonists represent a separate pharmacodynamic concern: AOD-9604's proposed effect on adipose metabolism could theoretically alter insulin sensitivity, though human data to quantify that effect are absent 1.

Patients using AOD-9604 for body composition alongside a full cardiometabolic medication stack (statin, ACE inhibitor or ARB, metformin, GLP-1 receptor agonist) should have the entire regimen reviewed by a physician familiar with peptide pharmacology before starting. That review should include a medication reconciliation list that explicitly captures all compounded agents.